SGCB and hydrops fetalis: Vericiguat, a soluble guanylate cyclase (sGC) stimulator, gained approval in several countries between 2021 and 2022 for HFrEF, showing benefit in reducing the risk of hospitalization for HF or the need for urgent intravenous diuretics [117].